BioLineRx (BLRX) Reports Q3 Loss of $0.06/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to BioLineRx (BLRX) Reports Q3 Loss of $0.06/Share

BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 11, 2019 7:00 AM EST

TEL AVIV, Israel, Nov. 11, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2019 and provides a corporate update.  

Highlights and achievements during the third quarter 2019 and subsequent period:

Continued to advance its COMBAT/KEYNOTE-202 Phase 2a trial in collaboration with Merck, evaluating BL-8040 in combination with pembrolizumab and chemotherapy in metastatic pancreatic cancer; Obtained initial safety data from Part 1 of Phase 1/2a trial of... More